FIELD: chemistry; pharmaceutics; medicine.
SUBSTANCE: invention relates to chemistry, pharmaceutics and medicine, namely to a method for increasing brain tissue volume or preventing or delaying brain tissue volume loss in a subject. According to the proposed method, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof is administered to a subject, wherein the compound of formula (I) has the structure 
, in which R1 is hydrogen; R2 and R3 are independently selected from C1-3-alkyl; R4, R5 and R6 are independently selected from hydrogen and halogen; A is thiazolyl.
EFFECT: invention provides implementation of the purpose.
17 cl, 1 dwg, 19 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | 2020 |
|
RU2824599C2 |
| METHODS OF TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | 2020 |
|
RU2829786C2 |
| COMPOUNDS AND METHODS | 2015 |
|
RU2711442C2 |
| GLUCOSYLCERAMIDE-SYNTHASE INHIBITORS | 2012 |
|
RU2645675C2 |
| 4-OXO-3,4-DIHYDROQUINAZOLINONE COMPOUNDS FOR TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2021 |
|
RU2814662C1 |
| ORGANIC COMPOUNDS | 2015 |
|
RU2709786C2 |
| HISTONE DEACETYLASE INHIBITORS | 2014 |
|
RU2673819C2 |
| AMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR APPLICATION METHODS | 2017 |
|
RU2759913C2 |
| INTEGRATED STRESS PATHWAY PRODRUG MODULATORS | 2019 |
|
RU2824500C2 |
| SOBETIROME DERIVATIVES | 2017 |
|
RU2776372C2 |
